Product details
Catalog number BNUB0429-500
Price for BNUB0429-500
Size / count 1x 500 µL
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
The catalog number for CD19 (CVID3/429), 0.2mg/mL is BNUB0429-500.
CD19 (CVID3/429), 0.2mg/mL is available in the following size(s): 1x 500 µL.
CD19 (CVID3/429), 0.2mg/mL is currently made to order / not held in immediate stock. Contact us for lead time.
CD19 (CVID3/429), 0.2mg/mL is manufactured by Biotium.
Estimated delivery time for CD19 (CVID3/429), 0.2mg/mL is approximately 15 business day(s), depending on your location.
The safety data sheet for CD19 (CVID3/429), 0.2mg/mL is available here: https://cdn.gentaur.com/products/37/68dd029a061270361e1014f6/msds/bnub0429-500.pdf.
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is
Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.
Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.
A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.